Telix Doses First Patient in Phase 3 LUTEON Trial of TLX250-Tx for Renal Cancer

Phase 3TLX250-TxPositive

AI Analysis

Summary

Telix Pharmaceuticals announced first patient dosing in the LUTEON Phase 3 trial of TLX250-Tx, a radiopharmaceutical targeting CAIX for relapsed or recurrent clear cell renal cancer (ccRCC). This marks the first radiopharmaceutical therapy to enter Phase 3 development for this indication.

Clinical Trial Data

Phase

Phase 3

Outcome Details

First patient dosed in LUTEON Phase 3 trial

Importance:7/10

Sentiment:

0.60

radiopharmaceuticaloncologyrenal cancerCAIX-targetingPhase 3 initiation

Related Companies

$TLX

Read the original article

Published by GlobeNewswire Clinical Studies on July 20, 2026 9:00 PM

Read Original